M

Mankind Pharma Ltd
NSE:MANKIND

Watchlist Manager
Mankind Pharma Ltd
NSE:MANKIND
Watchlist
Price: 2 350.25 INR -0.92%
Market Cap: 969.7B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one MANKIND stock under the Base Case scenario is 2 487.67 INR. Compared to the current market price of 2 350.25 INR, Mankind Pharma Ltd is Undervalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MANKIND Relative Value
Base Case
2 487.67 INR
Undervaluation 6%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

8.1
P/S
P/S
Price to Sales
8.1
vs History
41
vs Industry
18
Median 3Y
7.6
Median 5Y
7.6
Industry
2.4
Forward
7.5
More Details
46
P/E
P/E
Price to Earnings
46
vs History
33
vs Industry
9
Median 3Y
42.5
Median 5Y
42.5
Industry
20.5
Forward
45.2
More Details
40.4
P/OCF
P/OCF
Price to OCF
40.4
vs History
20
vs Industry
11
Median 3Y
0
Median 5Y
0
Industry
15.4
More Details
43.5
P/FCFE
P/FCFE
Price to FCFE
43.5
vs History
20
vs Industry
12
Median 3Y
0
Median 5Y
0
Industry
22.6
More Details
8.9
P/B
P/B
Price to Book Value
8.9
vs History
58
vs Industry
7
Median 3Y
9.2
Median 5Y
9.2
Industry
2
More Details
7.8
EV/S
EV/S
Enterprise Value to Sales
7.8
vs History
41
vs Industry
17
Median 3Y
7.3
Median 5Y
7.3
Industry
2.5
Forward
7.1
More Details
10.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.9
vs History
41
vs Industry
17
Median 3Y
10.3
Median 5Y
10.3
Industry
4.9
More Details
31.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
31.5
vs History
45
vs Industry
10
Median 3Y
30
Median 5Y
30
Industry
12.6
Forward
27.5
More Details
37
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
37
vs History
41
vs Industry
10
Median 3Y
35.3
Median 5Y
35.3
Industry
15.6
Forward
33.7
More Details
38.9
EV/OCF
EV/OCF
Enterprise Value to OCF
38.9
vs History
20
vs Industry
11
Median 3Y
0
Median 5Y
0
Industry
13.9
More Details
47.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
47.4
vs History
20
vs Industry
10
Median 3Y
0
Median 5Y
0
Industry
17.7
More Details
11.7
EV/IC
EV/IC
Enterprise Value to IC
11.7
vs History
29
vs Industry
10
Median 3Y
10.8
Median 5Y
10.8
Industry
1.8
More Details

Multiples Across Competitors

MANKIND Competitors Multiples
Mankind Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Mankind Pharma Ltd
NSE:MANKIND
941.6B INR 8.1 46 31.5 37
US
Eli Lilly and Co
NYSE:LLY
819.5B USD 18.2 77.4 44.9 49.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
393B USD 4.4 27.9 13.1 17.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 8 22.9 15.1 17.1
CH
Roche Holding AG
SIX:ROG
242.5B CHF 4.1 21.1 11.7 13.9
US
Merck & Co Inc
NYSE:MRK
233.7B USD 3.6 13.7 9.2 10.9
UK
AstraZeneca PLC
LSE:AZN
177.6B GBP 4.2 32.6 126.9 193.9
CH
Novartis AG
SIX:NOVN
199.6B CHF 4.4 18.9 11.4 14.7
IE
Endo International PLC
LSE:0Y5F
166.1B USD 71.6 -56.8 265.3 665.3
US
Pfizer Inc
NYSE:PFE
148.1B USD 2.3 18.4 8.7 12.5
P/E Multiple
Earnings Growth PEG
IN
M
Mankind Pharma Ltd
NSE:MANKIND
Average P/E: 31
46
17%
2.7
US
Eli Lilly and Co
NYSE:LLY
77.4
48%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.9
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
22.9
19%
1.2
CH
Roche Holding AG
SIX:ROG
21.1
16%
1.3
US
Merck & Co Inc
NYSE:MRK
13.7
17%
0.8
UK
AstraZeneca PLC
LSE:AZN
32.6
36%
0.9
CH
Novartis AG
SIX:NOVN
18.9
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
M
Mankind Pharma Ltd
NSE:MANKIND
Average EV/EBITDA: 398.6
31.5
31%
1
US
Eli Lilly and Co
NYSE:LLY
44.9
30%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
15%
1
CH
Roche Holding AG
SIX:ROG
11.7
8%
1.5
US
Merck & Co Inc
NYSE:MRK
9.2
9%
1
UK
AstraZeneca PLC
LSE:AZN
126.9
9%
14.1
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
265.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.7
3%
2.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
M
Mankind Pharma Ltd
NSE:MANKIND
Average EV/EBIT: 1 703.1
37
21%
1.8
US
Eli Lilly and Co
NYSE:LLY
49.6
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
17.1
16%
1.1
CH
Roche Holding AG
SIX:ROG
13.9
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.9
12%
0.9
UK
AstraZeneca PLC
LSE:AZN
193.9
21%
9.2
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
IE
E
Endo International PLC
LSE:0Y5F
665.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.5
10%
1.2

See Also

Summary
MANKIND intrinsic value, competitors valuation, and company profile.
DCF Valuation
MANKIND stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MANKIND stock valuation using valuation multiples.
Wall Street Estimates
MANKIND price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MANKIND stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.